MAPK3 and cancer: Those results confirm our previous studies that thyroxine via integrin αvβ3 activates the ERK1/2-dependent signal transduction pathway to modulate proliferation in cancer cells (Lin et al., 2013; Davis et al., 2014; Davis et al., 2015; Lin et al., 2016a; Lin et al., 2016b).